Literature DB >> 33427889

[Using preorchiectomy tumor marker serum concentrations for International Germ Cell Consensus Classification (IGCCCG) risk group assignment results in significant numbers of up- and downstaging].

Pia Paffenholz1, Tim Nestler2, Yasmine Maatoug3, Melanie von Brandenstein3, Barbara Köditz3, David Pfister3, Axel Heidenreich3,4.   

Abstract

BACKGROUND: The prognostic classification system of the International Germ Cell Cancer Cooperative Group (IGCCCG) for testicular germ cell tumors is based on the histological subtype, location of the primary tumor, extent of metastatic spread and prechemotherapy tumor marker serum concentrations.
OBJECTIVES: In this study, we aim to identify whether the use of preorchiectomy instead of prechemotherapy tumor marker serum concentration has an impact on IGCCCG risk group assignment.
MATERIALS AND METHODS: We performed a retrospective analysis including 135 patients with metastasized testicular germ cell tumors. Analysis of the clinical information with a focus on the tumor marker serum concentration preorchiectomy and prechemotherapy was performed, thus leading to the grouping of patients according to IGCCCG risk group assignment.
RESULTS: Using preorchiectomy instead of prechemotherapy tumor markers led to an incorrect IGCCCG risk group classification in 8% (11/135) of all patients, and consequently to a non-guideline concordant treatment. Up-staging was observed in 8 of 11 patients, representing 6% (8/135) of the total patient cohort. Three of the 11 misclassified patients showed a down-staging and thus describe 2% (3/135) of the total patient cohort.
CONCLUSIONS: Using preorchiectomy tumor markers instead of prechemotherapy serum concentration might lead to an incorrect IGCCCG risk group assignment as well as non-guideline concordant treatment. Consequently, prechemotherapy tumor marker serum concentration should be applied for guideline concordant staging of patients.

Entities:  

Keywords:  Chemotherapy; IGCCCG; Orchiectomy; Testicular germ cell tumors; Tumor marker serum concentration

Mesh:

Substances:

Year:  2021        PMID: 33427889      PMCID: PMC7979643          DOI: 10.1007/s00120-020-01432-1

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  10 in total

1.  Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer.

Authors:  J A Gietema; M T Meinardi; J Messerschmidt; T Gelevert; F Alt; D R Uges; D T Sleijfer
Journal:  Lancet       Date:  2000-03-25       Impact factor: 79.321

2.  Comprehensive Audiometric Analysis of Hearing Impairment and Tinnitus After Cisplatin-Based Chemotherapy in Survivors of Adult-Onset Cancer.

Authors:  Robert D Frisina; Heather E Wheeler; Sophie D Fossa; Sarah L Kerns; Chunkit Fung; Howard D Sesso; Patrick O Monahan; Darren R Feldman; Robert Hamilton; David J Vaughn; Clair J Beard; Amy Budnick; Eileen M Johnson; Shirin Ardeshir-Rouhani-Fard; Lawrence H Einhorn; Steven E Lipshultz; M Eileen Dolan; Lois B Travis
Journal:  J Clin Oncol       Date:  2016-06-27       Impact factor: 44.544

3.  Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer.

Authors:  Janine Nuver; Andries J Smit; Jan van der Meer; Maarten P van den Berg; Winette T A van der Graaf; Martin T Meinardi; Dirk Th Sleijfer; Harald J Hoekstra; Anne I van Gessel; Arie M van Roon; Jourik A Gietema
Journal:  J Clin Oncol       Date:  2005-11-21       Impact factor: 44.544

4.  [Long-term effects of cisplatin-based chemotherapy in testicular cancer patients-what is important?]

Authors:  Walter Albrecht
Journal:  Urologe A       Date:  2019-10       Impact factor: 0.639

5.  Pre-orchiectomy tumor marker levels should not be used for International Germ Cell Consensus Classification (IGCCCG) risk group assignment.

Authors:  Christian Daniel Fankhauser; Travis A Gerke; Lisa Roth; Sophia Sander; Nico Christian Grossmann; Benedikt Kranzbühler; Daniel Eberli; Tullio Sulser; Joerg Beyer; Thomas Hermanns
Journal:  J Cancer Res Clin Oncol       Date:  2019-01-14       Impact factor: 4.553

6.  Adherence to National Comprehensive Cancer Network® Guidelines for Testicular Cancer.

Authors:  Kevin M Wymer; Shane M Pearce; Kelly T Harris; Phillip M Pierorazio; Siamak Daneshmand; Scott E Eggener
Journal:  J Urol       Date:  2016-09-20       Impact factor: 7.450

7.  Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study.

Authors:  Sarah L Kerns; Chunkit Fung; Patrick O Monahan; Shirin Ardeshir-Rouhani-Fard; Mohammad I Abu Zaid; AnnaLynn M Williams; Timothy E Stump; Howard D Sesso; Darren R Feldman; Robert J Hamilton; David J Vaughn; Clair Beard; Robert A Huddart; Jeri Kim; Christian Kollmannsberger; Deepak M Sahasrabudhe; Ryan Cook; Sophie D Fossa; Lawrence H Einhorn; Lois B Travis
Journal:  J Clin Oncol       Date:  2018-04-04       Impact factor: 44.544

8.  The Novel Biomarker of Germ Cell Tumours, Micro-RNA-371a-3p, Has a Very Rapid Decay in Patients with Clinical Stage 1.

Authors:  Arlo Radtke; Finja Hennig; Raphael Ikogho; Johannes Hammel; Petra Anheuser; Christian Wülfing; Gazanfer Belge; Klaus-Peter Dieckmann
Journal:  Urol Int       Date:  2018-04-26       Impact factor: 2.089

9.  Non-Guideline-concordant Treatment of Testicular Cancer Is Associated With Reduced Relapse-free Survival.

Authors:  Pia Paffenholz; Isabel Maria Heidegger; Kathrin Kuhr; Sven Heiko Loosen; David Pfister; Axel Heidenreich
Journal:  Clin Genitourin Cancer       Date:  2017-09-06       Impact factor: 2.872

Review 10.  Long-term toxicity of cisplatin in germ-cell tumor survivors.

Authors:  M Chovanec; M Abu Zaid; N Hanna; N El-Kouri; L H Einhorn; C Albany
Journal:  Ann Oncol       Date:  2017-11-01       Impact factor: 32.976

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.